For this purpose, we analysed a large Japanese medical database using patients treated with dipeptidyl peptidase‐4 (DPP‐4) inhibitors as a reference group because these drugs have been available in Japan for ~8 years, have a complementary mechanism of action to SGLT2 inhibitors and, in our experience, are widely prescribed to patients with type 2 diabetes in Japan. Here, DPP4 is linked to type 2 diabetes mellitus.